Page last updated: 2024-11-03

probenecid and Osteosarcoma

probenecid has been researched along with Osteosarcoma in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aggarwal, S1
Gupta, S1

Other Studies

1 other study available for probenecid and Osteosarcoma

ArticleYear
A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63).
    International journal of oncology, 1998, Volume: 13, Issue:6

    Topics: ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Fibroblast Growth Factor 2; HL-60 Cell

1998